A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis. Researchers discovered that a high ratio of CXCL13 to BAFF indicates compartmentalized inflammation in the leptomeninges, a hallmark of progressive MS.
A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis. Researchers discovered that a high ratio of CXCL13 to BAFF indicates compartmentalized inflammation in the leptomeninges, a hallmark of progressive MS.
Share this Article
Recommended